

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Hutchison Whampoa Limited

(incorporated in Hong Kong with limited liability)
(Stock Code: 13)

OVERSEAS REGULATORY ANNOUNCEMENT

Please refer to the attached announcement of Hutchison China MediTech Limited, which is listed on the Alternative Investment Market operated by the London Stock Exchange and a 71.5% owned subsidiary of Hutchison Whampoa Limited.

As at the date of this announcement, the Directors of the Company are:

Executive Directors:

Mr LI Ka-shing (*Chairman*)
Mr LI Tzar Kuoi, Victor (*Deputy Chairman*)
Mr FOK Kin-ning, Canning
Mrs CHOW WOO Mo Fong, Susan
Mr Frank John SIXT
Mr LAI Kai Ming, Dominic
Mr KAM Hing Lam

Non-executive Directors:

Mr George Colin MAGNUS
Mr William SHURNIAK

Independent Non-executive Directors:

The Hon Sir Michael David KADOORIE
Mr Holger KLUGE
Mrs Margaret LEUNG KO May Yee
Mr William Elkin MOCATTA
*(Alternate to The Hon Sir Michael
David Kadoorie)*
Mr WONG Chung Hin

Hong Kong, 19 April 2010



HUTCHISON CHINA MEDITECH LTD

**Hutchison China MediTech Limited (“Chi-Med”)
(AIM: HCM)**

Seven-year extension of IP protection for Chi-Med’s main prescription drug

London: Monday, 19 April 2010: Chi-Med today announces that its main proprietary prescription drug, She Xiang Bao Xin pill (“SXBXP”), for the treatment of cardiovascular disease, has gained a seven-year extension of its “Confidential State Secret Technology” status as certified by China’s Ministry of Science and Technology and State Secrecy Bureau. This effectively extends full intellectual property protection of SXBXP until December 2016 by prohibiting generic registrations.

SXBXP is produced and distributed by Shanghai Hutchison Pharmaceuticals Limited (“SHPL”), Chi-Med’s 50% owned prescription drug joint venture, part of its China Healthcare Division. SHPL is the only manufacturer and distributor of SXBXP. In 2009, contribution of SXBXP’s sales to Chi-Med’s China Healthcare Division grew 41% to US\$22.4 million (2008: US\$15.8m). Sales of SXBXP represented over 82% of SHPL’s total sales in 2009 and over 800 million doses of the drug.

SXBXP holds market-leading shares in the prescription cardiovascular drug market in eastern China with market shares of 30.4% in Shanghai, 19.8% in Nanjing and 27.6% in Hangzhou (IMS Health data 2009).

In September 2009, SXBXP was included on China’s Essential Medicines List of 307 drugs that are now mandatory for all state-owned health institutions in China to carry. Furthermore, in December 2009, SXBXP had its Type-A drug status renewed in the latest edition of the Medicines Catalogue announced by the Ministry of Human Resources and Social Security in China, which means it is fully reimbursed in all provinces under the national medical insurance, labour injury insurance and child birth insurance systems in China.

Christian Hogg, CEO of Chi-Med, said: “The extension of protection on SXBXP is an important achievement which, in combination with inclusion on the Essential Medicines List and Type-A status on the Medicines Catalogue in China, should help our China Healthcare Division maintain its positive momentum.”

Ends

Enquiries

Chi-Med

Christian Hogg, CEO

Telephone: +852 2121 8200

Citigate Dewe Rogerson

Anthony Carlisle

David Dible

Telephone: +44 (0) 20 7638 9571

+44 (0) 7973 611 888

+44 (0) 7967 566 919

Lazard & Co., Limited

Paul Gismondi

Nick Fowler

Telephone: +44 (0) 20 7187 2000

About Chi-Med

Chi-Med is the holding company of a pharmaceutical and healthcare group based primarily in China and was admitted to trading on the Alternative Investment Market of the London Stock Exchange in May 2006. It is focused on researching, developing, manufacturing, and selling pharmaceuticals and health oriented consumer products.

Chi-Med is majority owned by Hutchison Whampoa Limited, an international company listed on the Main Board of The Stock Exchange of Hong Kong Limited.